IRVINE, Calif., April 2, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in
IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth
IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into
Irvine, Calif., Jan. 8, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as
Irvine, Calif., January 6, 2025 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a leader in diagnostic technology, today announced a significant milestone in the
New York, New York, December 13, 2024 – PRISM MediaWire continued to spotlight groundbreaking stories and transformative announcements shaping industries worldwide this week. From innovative
January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 – PRISM MediaWire – Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today
IRVINE, Calif., Dec. 04, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding
PRISM MediaWire
info@prismmediawire.com
Phone: 646-780-8850
